Weak consumer sales and flat medical device and diagnostics sales didn't stop Johnson & Johnson from trouncing analyst estimates Monday--or from raising its guidance for the year. A lineup of hot new meds powered the drug giant's first-quarter performance, helping pharma sales climb nearly 11% to $7.5 billion.
J&J says that it is discontinuing work on the neurotoxin program for PurTox, its long-acting successor to Botox, even though its Mentor subsidiary has wrapped three late-stage studies on the aesthetic therapy for smoothing out facial wrinkles.
Scripps' two big research outfits in California and Florida have allied themselves with the J&J Innovation Center in Menlo Park, CA, in an effort designed to take some of their early-stage breakthroughs and spin off new development programs, looking to kick-start a few biotech startups and Big Pharma match-ups along the way.
Three years ago, Sanofi walked away from a $375 million diabetes partnership with Metabolex, which had just salved the wound with a new pact with J&J. Now, operating under a new name--CymaBay--and armed with a fresh $38 million raise from late last year, the small biotech is floating plans for a $30 million IPO, looking to cash in on the lingering biotech boom.
Johnson & Johnson and Bayer's Xarelto made its way to the front of the new-age anticoagulant pack not long after hitting the U.S. market, gaining ground from rival Pradaxa to head what has since become a three-horse race. And that's ground its makers aren't ready to cede.
A Johnson & Johnson number cruncher says nuggets of marketing gold are waiting to be found on its parenting site BabyCenter.
Johnson & Johnson is using a research panel of 50,000 consumers, together with sharing-minded mothers on its parenting site BabyCenter, to flag ideas and catchphrases that resonate with moms.
Johnson & Johnson's Ethicon arm has been ordered to pay $1.2 million in damages in a trial alleging it produced faulty vaginal mesh that was implanted into a 64-year-old woman.
Johnson & Johnson has formally accepted the Carlyle Group's $4 billion-plus bid to snatch up its Ortho Clinical Diagnostics arm, more than two months after announcing the proposed transaction.
Denmark's Genmab is rolling right along with breakthrough-designated daratumumab for double refractory multiple myeloma, hitting a milestone in Phase II development and triggering a $22 million payout from collaborator Johnson & Johnson.